Propranolol in Schizophrenia

Ridges, A. Pauline; Lawton, Kenneth; Harper, P.; Ghosh, Chinmoy; Hindson, N.

doi:10.1016/s0140-6736(77)90939-4

Cited by 26 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Review of the studies in table 1, part I suggests that propranolol alone may be no better than placebo or neuroleptics in the treatment of either acute or chronic treatment-re sistant schizophrenic patients. Although in seven uncontrolled trials of propranolol in drug-free, neuroleptic-refractory schizophrenic patients, five suggested a positive effect (Atsmon et al 1972; Ridges et al 1977; Belmaker et al 1979; Elizur et al 1979; Hanssen et al 1980), the single randomized trial of propranolol alone in this population was negative (Peet et al 1981).…”

Section: Summary Of Clinical Findingsmentioning

confidence: 99%

One More Look at Propranolol for the Treatment of Refractory Schizophrenia

Berlant

1987

Schizophrenia Bulletin

View full text Add to dashboard Cite

Propranolol, a beta-adrenergic blocking agent, has been proposed previously as potentially useful in the treatment of certain otherwise treatment-unresponsive psychotic patients. This article reviews the published clinical trials of the efficacy of propranolol in schizophrenia to characterize those patients in whom it might be helpful and for whom future clinical trials should be designed. Despite a large number of inconsistent reports, the evidence to date favors its potential value as an adjunct to neuroleptic therapy in neuroleptic-resistant chronic schizophrenic patients. Several recommendations are made to improve the methodology of future clinical trials with this agent for the treatment of schizophrenia.

show abstract

Section: Summary Of Clinical Findingsmentioning

confidence: 99%

One More Look at Propranolol for the Treatment of Refractory Schizophrenia

Berlant

1987

Schizophrenia Bulletin

View full text Add to dashboard Cite

show abstract

“…Because of the cardiovascular effects of this drug double-blind studies are difficult to achieve and its anti-psychotic efficiency is not certainly established. It has been suggested that at the dosages used in the treatment of psychoses, propranolol does elevate prolactin secretion (Nasrallah, Freed, Rogol & Wyatt, 1977) but the evidence on this matter is conflicting (Hanssen, Heyden, Sundberg, Wetterburg & Enroth, 1978;Ridges, Lawton, Harper, Ghosh & Hindson, 1977). It is generally held that the action of neuroleptics on PRL secretion is a direct one on the pituitary.…”

Section: Pituitary Hormonementioning

confidence: 99%

Neuroendocrine markers of CNS drug effects.

Johnstone¹,

Ferrier²

1980

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Indirect evidence has come from pharmacological investigations, pointing out: 1) the NA receptor blocking activity of neuroleptics (8,9), significantly correlated, at least in some neurophysiological ULperiments (lo), with their antipsychotic potency; 2) the antipsychotic activity of some beta-adrenoceptor blocking agents, such as propranolol (11)(12)(13)(14), pindolol (15), acebutolol (16) and oxprenolol (17), and of the presynaptic alpha-adrenoceptor stimulant clonidine (18); 3) the worsening of psychotic symptoms induced in schizophrenics by the NA reuptake inhibitor imipramine (19) and by the presynaptic alpha-adrenoceptor blocker yohimbine (20); 4) the significant carrelation between the decrease of CSF NA induced by pimozide and the antipsychotic effect of this drug (21).…”

mentioning

confidence: 99%

Relationship between CSF noradrenaline levels, C‐EEG indicators of activation and psychosis ratings in drug‐free schizophrenic patients

Kemali

Maj

Iorio

et al. 1985

Acta Psychiatr Scand

View full text Add to dashboard Cite

A significant increase of cerebrospinal fluid (CSF) noradrenaline (NA) levels, probably reflecting a rise of central noradrenergic activity, has been observed in a sample of acute schizophrenic patients as compared with a population of subjects without personal or family history of major psychoses. CSF NA levels have been found to be significantly correlated with computerized EEG (C-EEG) indicators of arousal (negative correlation with alpha relative activity and positive correlation with alpha barycentric frequency and beta relative activity in frontal and central leads). No significant relationship has emerged between CSF NA concentration and psychosis ratings on CPRS as well as platelet MAO activity. These findings seems to confirm the link between central noradrenergic hyperactivity and the condition of enhanced arousal of the schizophrenic patient, although the role of this condition in the pathophysiology of schizophrenia (primary phenomenon or non-specific consequence of the stress related to the illness?) remains to be elucidated.

show abstract

Propranolol in Schizophrenia

Cited by 26 publications

References 7 publications

One More Look at Propranolol for the Treatment of Refractory Schizophrenia

One More Look at Propranolol for the Treatment of Refractory Schizophrenia

Neuroendocrine markers of CNS drug effects.

Relationship between CSF noradrenaline levels, C‐EEG indicators of activation and psychosis ratings in drug‐free schizophrenic patients

Contact Info

Product

Resources

About